Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan.

"Disclosure Dr Mariane S Fontes reports personal fees and travel expenses from Janssen Brazil, Astellas, MSD, AstraZeneca, Zodiac; personal fees from Bayer and Amgen, during the conduct of the study. Dr Daniel Vargas Pivato de Almeida reports personal fees from Astellas, AstraZeneca, Bayer, Eli Lilly, Ipsen, Janssen-Cilag, and Sanofi-Aventis, outside the submitted work. Dr Clarissa Cavalin reports personal fees and/or non-financial support from Bayer, Eli Lilly, AstraZeneca, and Novartis, outside the submitted work. Dr Scott T Tagawa reports grants and/or personal fees from Gilead, Seagen, Janssen, EMD Serono, and Merck, outside the submitted work. In addition, Dr Scott T Tagawa has a patent (biomarkers for sacituzumab govitecan therapy [Immunomedics / Gilead / Weill Cornell) issued to Gilead. The authors report no other conflicts of interest in this work."